Inhibitor Therapeutics, Inc. (INTI)
INTI is quoted over the counter, not listed on an exchange. Inhibitor Therapeutics, Inc. files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.
Closes: Yahoo Finance daily closes, last bar 2026-11-13.
Profile
| Field | Value |
|---|---|
| Ticker | INTI, quoted over the counter |
| SEC CIK | 0001042418 |
| OTC Markets tier | OTCQB (price source, 2026-11-13) |
| SEC industry code | Pharmaceutical Preparations |
| Business address | Tampa, FL |
| Incorporated in | DE |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions and events raise substantial doubt about the Company's ability to continue as a going concern." | 10-Q 2026-08-14 |
| Cash and burn | $516K cash; operating cash flow -$806K a quarter. | Report 2026-06-30 |
| Shares outstanding | 173,791,968 (2026-08-14); 172,573,545 a year earlier; 171,998,545 three years earlier. | Cover page 2026-08-14 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Cherry Bekaert LLP, Tampa, Florida, United States | PCAOB Form AP 2026-03-26 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$614K | -$775K | $516K | $48K | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | Not filed | -$686K | -$1.1M | $1.3M | $58K | Needs four quarters | 10-Q 2026-08-14 |
| Q4 2025 2025-12-31 | Not filed | -$1.3M | -$601K | $2.4M | $62K | Needs four quarters | 10-K 2026-03-26 |
| Q3 2025 2025-09-30 | Not filed | -$712K | -$761K | $3.0M | $72K | Needs four quarters | 10-Q 2025-11-13 |
| Q2 2025 2025-06-30 | Not filed | -$660K | -$584K | $3.7M | $78K | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | Not filed | -$633K | -$1.3M | $4.3M | $84K | Needs four quarters | 10-Q 2026-08-14 |
| Q4 2024 2024-12-31 | Not filed | -$1.4M | -$771K | $5.6M | No debt tags | Needs four quarters | 10-K 2026-03-26 |
| Q3 2024 2024-09-30 | Not filed | -$731K | -$720K | $6.4M | No debt tags | Needs four quarters | 10-Q 2025-11-13 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | POS AM | 2019-04-26 |
| Latest annual report | 10-K | 2026-03-26 |
| Latest quarterly / interim | 10-Q | 2026-11-16 |
| Latest current report | 8-K | 2026-09-18 |
| Latest proxy | DEF 14A | 2026-08-17 |
Source: SEC EDGAR submissions feed, 725 recent filings. All filings on EDGAR.
The full dossier has every filing, quarterly and annual financials, the health record and a price chart.
Open the full dossier